Zheng Quan Zhi Xing·2025-08-29 00:07Group 1 - CITIC Prudential Fund recently conducted research on two listed companies: Jiuan Medical and Nengke Technology [1] - Jiuan Medical's new product for 2024 utilizes colloidal gold immunochromatography technology for qualitative detection of influenza A, B, and Covid viruses, and is now a common home virus screening tool in the US market [1] - Nengke Technology reported that revenue growth from AI products and services is supported by external environment and internal strategies, with a clear trend towards smart manufacturing upgrades [1] Group 2 - Nengke Technology's gross margin improvement is attributed to business and product structure adjustments, focusing on high-margin sectors while reducing inefficient operations [1] - The company is in the early stages of vertical application development, with significant R&D investment and a long development cycle, aiming to enhance market share through continuous innovation [1] - CITIC Prudential Fund has an asset management scale of 162.93 billion yuan, ranking 44th among 210 funds, with a recent top-performing fund showing a 96.13% growth over the past year [2]